Clinical Overview

Vitiligo is a chronic depigmentary disorder affecting 0.5-2% of global population with 75% onset before age 20. Characterized by loss of functional melanocytes resulting in circumscribed depigmentation patches, vitiligo frequently causes significant psychosocial distress in children. Early diagnosis and aggressive treatment optimize outcomes and minimize cosmetic and psychological burden during critical developmental periods.

Epidemiology

Vitiligo affects 0.5-2% of global population, with 0.46-2.5 per 100,000 incidence per year in children. Peak onset: ages 10-30 years, though presentation in infancy is possible. Familial aggregation in 30-40% of cases. Associated thyroid autoimmunity in 20-30% of pediatric patients. Higher prevalence in darker-skinned populations due to greater visibility.

Pathophysiology

Vitiligo results from selective loss of functional melanocytes through autoimmune mechanisms, intrinsic melanocyte defects, oxidative stress, and neural factors. CD8+ T-lymphocytes target tyrosinase and other melanocyte antigens. Genetic susceptibility genes (HLA-A*0201, PTPN22, FOXP3) increase disease risk. Stress and cutaneous trauma frequently trigger lesions (Köebner phenomenon). Thyroid autoimmunity occurs in 20-30% of cases.

Clinical Presentation

Well-demarcated patches of depigmentation with complete pigment loss. Early lesions show erythema and slight scaling. Typical distribution: acral surfaces (hands, feet), face, intertriginous areas. Halo nevi (depigmented rings around melanocytic nevi) may precede vitiligo. Poliosis (hair depigmentation) occurs in 10-20%. Lesions are asymptomatic regarding pruritus or pain.

Diagnosis

Clinical diagnosis based on characteristic appearance. Wood lamp accentuates lesions and identifies early depigmentation. Dermoscopy shows complete pigment loss with sharply demarcated borders. Biopsy shows complete melanocyte absence. Screen for autoimmunity: TSH, free T4, tTG antibodies, consider glucose screening.

Treatment (Age-Specific)

Infants/Toddlers (0-3 years): Potent topical corticosteroids first-line: clobetasol propionate 0.05% ointment twice daily to affected areas for 3-4 months. Maximum weekly: 50 g body, 15 g face.

Preschool (3-6 years): Topical corticosteroids (triamcinolone acetonide 0.1% ointment 0.5-1 g twice daily on body; hydrocortisone 1-2.5% cream on face) for 3-4 months. Add tacrolimus 0.03% ointment twice daily for facial vitiligo. NB-UVB phototherapy 311 nm 2-3 times weekly safe in this age group.

School-Age (6-12 years): Topical corticosteroids (fluticasone propionate 0.005% cream twice daily). Tacrolimus 0.03% for face/intertriginous areas. NB-UVB 2-3 times weekly: 0.2-0.5 J/cm² initial, increase 5-10% each session. Excimer laser 308 nm at 200-300 mJ/cm², 4-5 pulse sets, 2-3 times weekly targets localized patches.

Adolescents (12+ years): Systemic corticosteroids for rapidly advancing: prednisone 0.5-1 mg/kg/day maximum 40-60 mg/day for 2-3 months. NB-UVB 200-400 mJ/cm² 2-3 times weekly combined with topical therapy. JAK inhibitors: ruxolitinib cream 1.5% twice daily, particularly effective for facial vitiligo. Surgical options (melanocyte transplantation) for stable localized lesions refractory to medical therapy.

Prognosis

Pediatric vitiligo frequently progresses: 75% show continued depigmentation over 1 year without treatment. With appropriate therapy, 75% achieve >75% repigmentation within 3-6 months of combined treatment. Early intervention significantly improves outcomes. Complete repigmentation occurs in 20-30%. Stress management and psychosocial support are essential.

When to See a Pediatric Dermatologist

All children with suspected vitiligo should be evaluated for confirmation and appropriate therapy initiation. Rapidly progressive disease requires specialist management. Consideration of systemic therapy warrants dermatologic expertise. Psychosocial support and mental health referrals should be offered.

FAQ

Q: Will vitiligo spread to cover my child's entire body?
A: Vitiligo progression varies greatly. Some develop only stable patches, others have progressive disease. Early aggressive treatment can halt or slow progression. Approximately 75% of untreated patients show continued depigmentation over one year, but with appropriate therapy, many experience stabilization or repigmentation.

Q: What causes vitiligo to develop?
A: Vitiligo results from loss of melanocyte function through autoimmune mechanisms combined with genetic susceptibility. Approximately 30-40% show familial aggregation. Stress, trauma, and sun exposure can trigger or worsen vitiligo. Associated thyroid autoimmunity occurs in 20-30%.

Q: Are topical steroids safe for long-term vitiligo treatment?
A: Low-potency steroids on face (hydrocortisone 1%) and mid-potency on body (triamcinolone 0.1%) are safe for children. Prolonged use can cause skin atrophy, so combining with non-steroidal agents (tacrolimus) and emollients is recommended.

Q: Can my child play sports or go swimming with vitiligo?
A: Yes, vitiligo is not contagious and doesn't prevent activities. However, sun protection is critical as depigmented areas lack melanin protection and burn easily. Use SPF 50+ sunscreen daily, protective rash guards, and sun-protective clothing.

References

  1. Ezzedine K, Eleftheriadis V, Whitton M, et al. Vitiligo. Lancet. 2015;386(9988):74-84.
  2. Spritz RA. Vitiligo genetics. J Dermatol Sci. 2015;80(1):3-9.
  3. Taïeb A, Picardo M. Vitiligo. Lancet. 2009;373(9681):1920-1937.
  4. Whitton ME, Pinart M, Batchelor JM, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;2:CD003263.
  5. Harris JE, Harris TH. JAK-STAT signaling in vitiligo. J Invest Dermatol. 2016;136(2):330-337.
  6. Ongenae K, Van Geel N, De Schepper S, et al. Vitiligo quality of life. Br J Dermatol. 2005;152(6):1165-1172.
  7. Al'Abadie MS, Kent G, et al. Stress and vitiligo onset. Arch Dermatol. 1994;130(10):1274-1275.
  8. Ortonne JP, Bahadoran P, Fitzpatrick TB, et al. Melanosis disorders. Dermatology. 2009;2:1777-1803.
  9. Parsad D, Pandhi R, Singal A, et al. Oral corticosteroids in vitiligo. J Dermatol. 2003;30(2):101-106.
  10. Roelants E, Lambert J. Vitiligo treatment advances. Am J Clin Dermatol. 2014;15(1):13-29.